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Abstract
Background: The Global Plan to Stop TB estimates funding required in low- and middle-income countries to achieve TB
control targets set by the Stop TB Partnership within the context of the Millennium Development Goals. We estimate the
contribution and impact of Global Fund investments under various scenarios of allocations across interventions and regions.
Methodology/Principal Findings: Using Global Plan assumptions on expected cases and mortality, we estimate treatment
costs and mortality impact for diagnosis and treatment for drug-sensitive and multidrug-resistant TB (MDR-TB), including
antiretroviral treatment (ART) during DOTS for HIV-co-infected patients, for four country groups, overall and for the Global
Fund investments. In 2015, China and India account for 24% of funding need, Eastern Europe and Central Asia (EECA) for
33%, sub-Saharan Africa (SSA) for 20%, and other low- and middle-income countries for 24%. Scale-up of MDR-TB treatment,
especially in EECA, drives an increasing global TB funding need – an essential investment to contain the mortality burden
associated with MDR-TB and future disease costs. Funding needs rise fastest in SSA, reflecting increasing coverage need of
improved TB/HIV management, which saves most lives per dollar spent in the short term. The Global Fund is expected to
finance 8–12% of Global Plan implementation costs annually. Lives saved through Global Fund TB support within the
available funding envelope could increase 37% if allocations shifted from current regional demand patterns to a prioritized
scale-up of improved TB/HIV treatment and secondly DOTS, both mainly in Africa 2 with EECA region, which has
disproportionately high per-patient costs, funded from alternative resources.
Conclusions/Significance: These findings, alongside country funding gaps, domestic funding and implementation capacity
and equity considerations, should inform strategies and policies for international donors, national governments and disease
control programs to implement a more optimal investment approach focusing on highest-impact populations and
interventions.
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Introduction
The Global Plan to Stop TB for 2011 to 2015 (Global Plan),
developed by the Stop TB Partnership with major inputs from the
World Health Organization (WHO), sets out the level of
tuberculosis (TB) interventions and funding that National TB
Control Programs (NTPs) will need to reach Millennium De-
velopment Goal (MDG) 6 TB targets and the related targets set by
the Stop TB Partnership for 2015 (see next section). The Plan’s
cost projections are based on estimates of TB disease and deaths,
intervention targets and service implementation costs for low- and
middle-income countries (LMIC) [1].
Between 2003 and 2011, NTPs that had received funding from
the Global Fund had provided treatment to 8.6 million people
with sputum smear-positive TB [2]. In 2011, the Global Fund
provided 76% of the external financing for TB and multi-drug-
resistant TB (MDR-TB) control in LMIC and 11% of the total
funding for TB in these countries [3]. Between its launch in 2002
and the end of 2011, the Global Fund invested US$2.3 billion in
TB grants in 116 countries, and disbursed in 2010 US$512 million
in TB grants [4]. In 2010, the Global Fund estimated donor
pledges and projected income of US$11.7 billion for investment in
HIV, TB and malaria over 2011 to 2013 [5].
The Global Fund fosters a demand-driven model of co-funding
NTPs. Demand is moderated by the technical support provided to
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countries by international health agencies when developing
proposals to request funds, followed by an independent technical
expert review of these proposals on soundness and local
appropriateness of interventions and programs. By 2010, this
grant making model had resulted in an investment pattern among
countries in line with their overall share in burden, for each of the
three diseases [6].
Based on control priorities identified by technical agencies such
as the WHO, the Global Fund regularly updates its guidance to
countries on effective interventions it will finance. The Global
Fund Strategy 2012–2016 which commits to scaling-up TB
interventions according to the Global Plan [7] emphasises efficient
allocation of available financial resources to achieve maximum
health impact as measured by infections prevented, deaths averted
and lives saved. In this context, we explore allocation scenarios in
which available Global Fund financing could contribute to
implementing the Global Plan through 2015. We first estimate
total NTP costs and lives saved, separately for (i) diagnosis and
DOTS treatment of fully drug-susceptible TB cases (hereafter
DOTS), (ii) diagnosis and treatment of multi-drug-resistant TB
(hereafter MDR-TB), and (iii) antiretroviral treatment (ART)
during DOTS treatment for HIV-coinfected patients (hereafter
TB/HIV care), if Global Plan targets were fully met. To estimate
the Global Fund’s contribution, a base-case scenario allocates TB
grants among countries and regions following the demand-based
pattern observed over 2007 to 2009 [8]. We assume that
implementing NTPs would allocate grant funding between
DOTS, MDR-TB treatment and TB/HIV care, in proportion
to their needs for these services as determined in the Global Plan.
Against this base-case, we then evaluate different scenarios, in
which a changed distribution of grants among countries and
services either maximizes lives saved, or prioritizes the regions with
the largest burden of TB/HIV or MDR-TB.
The Global Plan to Stop TB, 2011–2015: Targets and
Financing Requirements
The overall goal of the Global Plan to Stop TB is to achieve the
MDG and Stop TB partnership targets set for 2015 [1]:
TB in the Millennium Development Goals (set for 2015):
Goal 6: Combat HIV/AIDS, malaria and other diseases
N Target 6c: Halt and begin to reverse the incidence of malaria
and other major diseases;
N Indicator 6.9: Incidence, prevalence and death rates associated
with TB;
N Indicator 6.10: Proportion of TB cases detected and cured
under DOTS.
Stop TB Partnership targets (set for 2015 and 2050)
N By 2015: Reduce prevalence and death rates by 50%,
compared with their levels in 1990;
N By 2050: Eliminate TB as a public health problem, defined as
a global incidence of active TB of less than one case per 1
million population per year.
Specific Global Plan targets for 2015, according to the major
components of the plan, include:
N DOTS: 6.9 million cases diagnosed, notified and treated
according to the DOTS approach, in 2015 alone (compared to
a baseline of 5.8 million in 2009 alone), with 90% of drug-
susceptible cases cured (compared to an actual treatment
success rate of 86% in high-burden countries at end-2009).
N TB/HIV: Expand the enrolment of HIV-coinfected TB
patients on ART, such that by 2015 all HIV-positive TB
patients – estimated at almost 1 million people in 2009– are
enrolled on ART. This target compares to 140,000 actual
ART enrolments per year as (an estimated 37% of need) of
mid-2010.
N MDR-TB: Diagnosis and treatment of 270,000 MDR-TB
patients in 2015, i.e. 61% of estimated total MDR-TB cases in
2008, with 100% of confirmed cases treated according to
international guidelines and an increase in the treatment
success rate of confirmed MDR-TB from the 2009 baseline of
60% to $75% by 2015 [1]. In comparison, in 2008 [1] and
2009 [9] 5% and 12% of MDR-TB cases had been detected,
respectively.
These targets have been based on a situation analysis of actual
progress in service delivery that NTPs made over 2006–2010.
Absolute numbers of treatments corresponding to these targets,
with a gradual scale-up from 2011 to 2015, are based on WHO
country estimates of the current burden of drug-susceptible,
MDR-TB and TB/HIV cases, projected forward to 2015 in a log-
linear model fitted to the 2005–2009 observed trend [9,10].
The corresponding funding requirements are an overall US$ 47
billion over 2011 to 2015, including almost US$ 37 million for
implementation and almost US$ 10 billion for research and
development. Specific funding requirements include:
N DOTS: US$ 22.6 billion
N MDR-TB: US$ 7.1 billion
N TB/HIV: US$ 2.8 billion.
In 2011, more than 40 countries reported to have used the
WHO’s TB planning and budgeting tool [44] in planning their
national strategies in line with recommendations and targets of the
Global Plan, and in 2011, all the 27 high-MDR-TB countries
produced new national MDR-TB plans in line with the Global
Plan.
Methods
Interventions and Countries Considered
We use Global Plan projections of anticipated numbers of TB
cases that will be detected in DOTS programs led by NTPs in
the period 2011 to 2015, and WHO estimates of TB cases in
2010 as a baseline [1]. We focus on low- and middle-income
countries, as high-income countries are ineligible for Global
Fund financing.
We used WHO country trend estimates, based on notification
and treatment outcome data reported annually by NTPs, to
project expected TB cases in the different patient categories of
DOTS, MDR-TB and TB/HIV care, and feasible numbers of
these detected and treated in each country in the Global Plan
[9,10]. Projections assume that Global Plan targets and funding
requirements are fully met, that all TB cases detected by NTPs are
first treated for drug-susceptible TB, and that a sub-set of these
subsequently get tested and treated for MDR-TB or receive ART
if co-infected with HIV. When we present estimates of numbers
treated and lives saved, the three patient categories are mutually
exclusive so the number of drug-susceptible TB cases does not
include MDR-TB or patients with active TB and HIV co-
infection. Cost projections for DOTS, however, include DOTS
treatments for all cases including those with MDR-TB and TB/
HIV, as all patients would have received DOTS first. The costs
labelled MDR and ART are then the additional costs of treating
Global Stop TB Plan and Global Fund Allocations
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MDR-TB or TB/HIV, over and above the costs incurred for the
DOTS treatment.
To explore different allocation scenarios, we divided countries
into four groups with distinct epidemiological and TB burden
characteristics, namely:
1. China and India, which together account for about a third of
all incident TB cases worldwide [9];
2. Eastern Europe and Central Asia (EECA), where the
prevalence of MDR-TB among TB cases is highest;
3. sub-Saharan Africa (SSA), where prevalence and impact of
TB/HIV is highest;
4. all other low- and middle-income countries (Table S1).
Per-patient Costs in NTP Budgets
Funding needs are based on country-specific needs and
targets as determined in the Global Plan, which also estimated
the per-person cost of DOTS, MDR-TB, and treatment and
care for HIV-co-infected TB patients, including ART for the
duration of DOTS treatment, in each group of countries
(Table 1). Cost assumptions (Table 2) were based on
expenditure data and national program budget projections
reported by NTPs to WHO [9]; for MDR-TB treatment the
cost estimation furthermore included costing studies in selected
countries [11,12,13].
Lives Saved
Lives saved were estimated using case fatality rates with and
without treatment for each category of patients. We chose a no-
treatment counterfactual for all three treatment categories, to
validly compare these interventions for their full potential health
benefit. The global average case fatality rates were derived from
published studies and systematic reviews identified through
a PubMed search, up to December 2011 [1,9,10,14,15,16], and
treatment outcome data reported by NTPs to WHO. Key search
terms included ‘‘Tuberculosis’’, ‘‘Mortality’’ and ‘‘Case fatality’’.
Relevant additional studies were obtained by screening reference
lists from relevant articles, and from the WHO’s TB library,
including publications in English and French as described in more
detail in [1,9,10,11,12,14,15,16].
Against a counterfactual of no treatment, every DOTS
treatment of a drug-susceptible HIV-uninfected case is assumed
to avert 0.33 deaths [15], and every treatment with ART of an
HIV-coinfected patient 0.50 deaths [14,16]. For MDR-TB, there
are no published empirical data on case fatality without treatment.
We estimated the average lives saved per MDR-TB treatment as
being 0.30, i.e. 90% of the lives saved per DOTS treatment, based
on the typical lower cure rates for MDR-TB than for DOTS, as
reported by NTPs to WHO [1,9].
Uncertainty ranges in lives saved were estimated to reflect the
wide variation among countries and populations in case fatality
rates, which is apparent from published research studies, and from
treatment outcomes reported by NTPs [9]. Model-based ranges
are 640% to 660% for the fatality rate within each case category
[10,17,18,19]; we applied an error of 50% to each fatality rate.
NTP Budgets and Funding Sources
Table 3 shows the sources of current funding for TB control in
each region in 2010. NTP budgets by source were based on data
reported to WHO in 2009 [9,20]. At aggregate level, domestic
funding accounted for 76% to 97% of total TB funding available,
including that from the Global Fund and other international
contributions. Sub-Saharan Africa (77% domestic overall, but
48% when South Africa is excluded), and China and India (76%)
are at the lower end of this range, whereas EECA covers 97% of
TB funding from domestic resources. Similarly, when domestic TB
expenditures are expressed as a proportion of Gross Domestic
Product (GDP), sub-Saharan Africa, and China and India spend
well below other regions, notably below EECA.
Projections of TB program expenditures funded by the
Global Fund were based on 2010 donor pledges and projected
income of US$11.7 billion for the replenishment period 2011 to
2013. Using the regional distribution of Global Fund disburse-
ments from 2007 to 2009 [6], we assumed that 16% of
financing would be allocated to TB over the next five years,
with the rest allocated to HIV/AIDS (49%), malaria (34%) and
health systems strengthening (captured within the three disease
areas). Projections assume a one-year time lag between
disbursements and program expenditures.
Allocation Scenarios
From 2007 to 2009, 32% of Global Fund TB disbursements
were in sub-Saharan Africa, 16% in India and China, 17% in
EECA, and 34% in other LMIC (Table 4). For the base-case
projections (Scenario A), we assumed that these regional
allocation patterns are maintained from 2011 to 2015. Base-case
projections furthermore assumed that, within each region,
Global Fund investments would be allocated to DOTS,
MDR-TB treatment and ART in proportion to their respective
funding needs according to the Global Plan. Scenario B then
considers the effect of re-allocating TB investments among
regions and interventions to maximize lives saved by Global
Fund financing. For comparison, a Scenario C explores what
would happen if the Global Fund’s policy were to first
Table 1. Assumed per-patient cost (US $) of projected TB interventions by country group.
Countries
Number of
countries DOTS MDR treatment
6 months of ART for TB/HIV
patient
China and India 2 503 4,315 271
Eastern Europe and Central Asia 16 5,582 9,299 273
Sub-Saharan Africa 46 503 4,315 236
Other low- and middle-income countries 85 503 4,315 250
Notes: Stated amounts reflect unit costs in US$ as of 2010, of (i) diagnosing and treating one TB patient under DOTS [1] and (ii) the additional cost incurred if the patient
has multi-drug resistant (MDR) TB as estimated in the WHO/Stop TB partnership Global Plan to Stop TB 2011–2015 [1], and (iii) the additional cost incurred if the patient
is HIV-positive and receives antiretroviral therapy (ART) for the duration of a 6-month DOTS course [47]. Costs are inflated at 3% per annum. Regional cost estimates
were based on country cost estimates, weighted by each country’s notified incident cases.
doi:10.1371/journal.pone.0038816.t001
Global Stop TB Plan and Global Fund Allocations
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exclusively finance DOTS with concurrent ART for HIV-
coinfected TB patients, and next MDR-TB treatment, before
contributing to DOTS for HIV-negative TB patients – as under
the Global Plan, treatment of HIV-coinfected TB patients and
MDR-TB both require a more rapid funding increase than does
DOTS [21].
Results
Service Coverage and Funding Needs
Overall Global Plan targets for LMIC in 2015 [1] are 6.9
million DOTS treatments for drug-susceptible TB, including 1.0
million people living with HIV, and 0.27 million MDR-TB
Table 2. Cost components borne by NTPs, included in the Global Plan to Stop TB, 2011–2015.
DOTS Laboratory diagnosis: sputum smears, including scale-up of fluorescent light-emitting diode microscopy to replace conventional light
microscopy, and X-rays
First-line drugs
Health workers and NTP staff
Programme management
Practical Approach to Lung Health
Private Public Mix
Community-based Care
Advocacy Communications and Social Mobilization
Operational research and surveys
MDR-TB Second- and third-line drugs
Hospitalization including infection control
DOT visits
Sputum smears, cultures, drug susceptibility testing with scale-up in the use of liquid culture media to replace solid media
Training, programme and data management
Provision of food parcels
TB/HIV Antiretroviral treatment for the six months’ duration of DOTS treatment, the period that TB and HIV treatment overlap. Initiation of ART during
DOTS treatment is a highly cost-effective, WHO-recommended intervention to reduce early mortality [45,46]
Notes: In addition to DOTS, management of MDR-TB and TB/HIV, the Global Plan includes estimates of costs for co-trimoxazole preventive therapy (CPT) during DOTS,
nutritional support, HIV serological testing and counselling for HIV-coinfected patients, and isoniazid-based preventive therapy (IPT) to prevent HIV-positive people with
latent Mycobacterium tuberculosis infection from developing active TB disease [1]. Our projections do not include these added costs, which are relatively small for CPT
(e.g. less than $10 per patient-year in Uganda [48]), difficult to express per TB patient for IPT, which concerns HIV-infected patients without active TB, and not necessarily
borne by NTPs for nutritional support and for HIV testing and counselling. Globally, uptake of IPT remains low, in spite of efforts by normative and financing agencies to
increase its implementation [49]. One factor contributing to this slow uptake is the absence of sensitive and specific tests distinguishing between active disease and
latent TB [49]; other factors warrant further exploration by the major normative and financing agencies for TB control.
doi:10.1371/journal.pone.0038816.t002
Table 3. Sources of funding for TB control, according to NTP preliminary 2010 budgets.
Amounts in millions of US$ China and India
Eastern Europe &
Central Asia Sub-Saharan Africa
Other low and middle-
income countries
All low and middle-
income countries
General health services 38 416 371 625 1,450
Government 230 1,540 273 327 2,370
Global Fund 63 67 124 133 387
Other grants 20 2 58 38 117
Total available 351 2,025 826 1,123 4,324
Domestic/Total 76% 97% 78% 85% 88%
Domestic/GDP 0.004% 0.094% 0.067% 0.012% 0.022%
Need 2015 1,912 2,562 1,564 1,850 7,888
Regional share of Global Fund TB
disbursements
16% 17% 32% 34% 100%
Notes: Preliminary NTP budgets for 2010 were reported to WHO by 107 of the 149 Global Plan countries, which together accounted for 98% of the global burden of TB
in 2009 [9]. According to these figures, $3.8 billion was available from domestic sources in 2010. This domestic contribution included approximately $1.5 billion spent on
general inpatient and outpatient health services, outside of NTP budgets, which were estimated based on costs and frequencies of hospital admissions and outpatient
visits to health facilities by TB patients [9,20].
Government: national governments including loans; Grants: external donors excluding the Global Fund; Total available = general health services + Government + Global
Fund + Other grants. Need: total TB control need, as defined in the 2010 Global Plan to Stop TB. Domestic = General health services + Government; GDP= gross
domestic product (purchasing power parity); Regional share of Global Fund=proportion of worldwide Global Fund TB disbursements going to each region, average
2007 to 2009.
doi:10.1371/journal.pone.0038816.t003
Global Stop TB Plan and Global Fund Allocations
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treatments (Box) [1]. To meet Global Plan targets across LMIC,
the total funding needed for the three interventions increases from
$5.0 billion in 2010 to $7.9 billion in 2015 (Figure 1). In
comparison, Global Plan cost estimates for overall control
implementation total just over $6 billion in 2011 and rise to
$8.5 billion in 2015, reflecting additional cost of co-trimoxazole
preventive therapy, nutritional support for HIV-coinfected
patients, HIV testing and counselling, and isoniazid-based pre-
ventive therapy for HIV-positive people with latent Mycobacterium
(M.) tuberculosis infection [1] (Table 2).
Regional Needs
In China and India (Figure 1: top), DOTS treatments fall
slowly, TB/HIV cases increase slowly (reflecting a stable, low
prevalence of HIV), but there is a large increase in patients treated
for MDR-TB. Funding needed increases from US$1.2 billion in
2010 to US$1.9 billion in 2015, mainly reflecting the cost of
treating MDR-TB in increasing numbers of people.
In EECA (Figure 1: second row) total treatments fall slowly, but
the decline in drug-susceptible TB will be balanced by increasing
MDR-TB. Since MDR-TB is more costly to treat, overall funding
need will increase by 25% between 2010 and 2015. By 2015, 62%
of total funding will be allocated to drug-susceptible TB, 37% to
MDR-TB and less than 1% to TB/HIV.
Sub-Saharan Africa (Figure 1: third row) accounts for the
largest number of people with TB/HIV among regions. In 2015,
40% of TB patients will be HIV-positive, but only about 2% will
have MDR-TB. The rapid increase in DOTS need reflects mainly
HIV-positive TB patients needing DOTS together with ART;
numbers of HIV-negative TB patients remain fairly constant.
In the other low- and middle-income countries (Figure 1:
fourth row), the greatest cost remains for treating drug-susceptible
TB (US$1.4 billion in 2015). Funding needed for MDR-TB
increases from near 0 in 2010 to US$317 million in 2015.
Across the four regions, in 2015 EECA will need the most
treatment funding and sub-Saharan Africa the least (Figure 1,
middle column and Table 4). In all regions the greatest need
remains for DOTS, the cost of which increases slightly over the
years, as per-patient costs rise [1]. However, in EECA 37% of
funding is needed for MDR-TB with a minimal need for TB/HIV,
whereas in sub-Saharan Africa 21% is needed for ART in HIV-
coinfected patients.
Lives Saved
Over 2011215, scaling up treatment will increase the annual
lives saved from 2.1 to 2.5 million (uncertainty ranges: 1.0 to 3.1
million, and 1.3 to 3.8 million, respectively), reflecting mainly
increasing treatments among HIV-coinfected patients (Figure 1).
MDR-TB treatment accounts for 4% of lives saved, corresponding
to its small share of treatments.
Among regions, about 800,000 lives (uncertainty range: 400,000
to 1,200,000) will be saved in each of China and India, sub-
Saharan Africa and other low- and middle-income countries. Only
about one-tenth as many lives will be saved in EECA, with fewer
patients than China & India or sub-Saharan Africa. Nevertheless,
this region needs most funding because of its large proportion of
MDR-TB treatments, and the high per-patient cost for both drug-
susceptible TB and MDR-TB (Table 1). The largest annual
increase in lives saved is in sub-Saharan Africa, where expected
intervention coverage increases most rapidly. In EECA, in
contrast, annual lives saved decrease slightly from 2010 to 2015,
reflecting the decline in DOTS treatment need following the
ongoing fall in case notifications.
Global Fund Contribution to TB Funding
Based on 2010 donor pledges and projected income, and
assuming the continuation of recent TB/HIV/malaria funding
allocation patterns, Global Fund TB investments will increase
from US$387 million in 2010 to $779 million in 2012, and then
fall to US$662 million in 2015 (Figure 2A). The peak in 2012 and
subsequent decline in annual expenditures reflects commitment
patterns over 201122013, of which the majority is used to renew
existing grants, with relatively smaller amounts available for new
programs [8].
In 2010, the Global Fund’s total TB expenditures of $387
million covered 7.7% of DOTS, MDR, and TB/HIV funding
need in LMIC (Figure 2B). This contribution would increase to
12.8% in 2012, then decline to 8.4% by 2015.
Global Fund Investment Scenarios Modelled
In base-case Scenario A, regional TB investments are aligned
with the regional distribution in total need (Figure 3a). Global
Fund financing would save on average 265,000 lives per year,
reaching 373,000 in 2015 (uncertainty range 186,0002559,000;
Figure 3c). Lives saved from DOTS, MDR-TB and TB/HIV
treatment (Figure 3c) are roughly proportional to treatment
numbers in these respective categories (Figure 3b). Only TB/HIV
treatments account for a larger proportion of lives saved compared
to their share of patients, because of the higher case fatality of
untreated TB/HIV co-infection compared to drug-susceptible TB
or MDR-TB without HIV.
Scenario B maximizes mortality impact from the funding
available. Of the three services, DOTS with concurrent ART for
TB/HIV patients saves most lives per dollar, within the 6-months
TB treatment duration considered as time horizon, in each region;
therefore this scenario first allocates enough grant money to fully
finance DOTS with concurrent ART for all HIV-coinfected
patients (Figure 3a). In 2015 alone, DOTS with concurrent ART
for TB/HIV patients worldwide would cost US$742 million,
absorbing 73% of the projected Global Fund resources for TB in
that year. The remaining 27% of available TB funding is then
allocated to treat HIV-uninfected, drug-susceptible TB in sub-
Saharan Africa, China and India, and other LMIC. If DOTS
allocations are distributed among these three regions in proportion
Table 4. Percentage distribution of funding need for
implementing DOTS, MDR-TB treatment and ART during
DOTS, over regions in 2015.
DOTS MDR ART
All
treatments
China and India 18.0 5.5 0.7 24.2
Eastern Europe and
Central Asia
20.3 12.1 0.1 32.5
Sub-Saharan Africa 13.8 1.8 4.2 19.8
Other low- and middle-
income countries
18.9 4.0 0.6 23.5
All low- and middle-
income countries
71.0 23.4 5.6 100.0
Notes: The projected total funding need for the three services in 2015 is US$7.9
billion according to the Global Plan to Stop TB 2011–2015 [1]. DOTS is the cost
of first-line DOTS for all TB cases including those with MDR-TB and/or
coinfected with HIV. MDR is the additional cost for treating those with MDR-TB
and ART the additional cost for treating those that are HIV-positive with ART for
six months during DOTS.
doi:10.1371/journal.pone.0038816.t004
Global Stop TB Plan and Global Fund Allocations
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to TB grants received over 2007–9, this will cover 19% of DOTS
need in sub-Saharan Africa, 8% in China and India, and 17% in
the other LMIC. This scenario would substantially increase
allocations to SSA countries (Figure 3a) and decrease allocations to
EECA, supported for just ART for their small number of HIV-
coinfected patients without Global Fund support for MDR-TB or
DOTS. Scenario B increases total lives saved in 2015 by 37% to
510,000 (255,0002765,000; Figure 3c).
In Scenario C, as in Scenario B, allocations covers DOTS with
ART for all HIV-coinfected TB patients, but remaining funding is
then allocated to MDR-TB in proportion to 2007–9 regional grant
patterns (Figure 3). Compared to the base-case, scenario C
increases allocations to SSA by 29%, slightly increases allocations
to EECA, and decreases allocations to other countries (Figure 3a).
A similar number of lives (222,000; range 111,0002332,000) are
saved among HIV-coinfected TB patients as in Scenario B, but
since all remaining funds are invested on costly MDR-TB
treatment mainly in EECA (Figure 3b), total lives saved are one-
third lower than in the base-case (Figure 3c).
Discussion
Our study is the first to synthesize worldwide data and estimates
of TB treatments, cost and funding from different sources, and
mortality impact expected over 2011 to 2015 in countries
worldwide, intoscenarios to optimize TB funding allocations
between regions and services. The projections show how the cost
of global TB control is driven by MDR-TB treatment need,
Figure 1. Cases of drug-susceptible TB, MDR-TB and HIV-related TB that will be found according to the Global Plan to Stop TB (left);
corresponding funding need (centre); and corresponding lives saved (right). Notes to Figure 1: Global Plan forecasts based on date
reported by NTPs to WHO up to 2009 [1,9]. Rows top to bottom: C&I: China and India; EE&CA: EECA; sub-Saharan Africa (SSA); L&MIC: Low- and
middle-income countries not included in the other three regions. The cost of DOTS for drug-susceptible TB, MDR-TB and TB/HIV patients is included
in ‘DOTS’ (blue circles & lines); yellow and pink bars cover the additional cost of providing MDR treatment or ART during DOTS treatment. Note that
vertical axes do not start from zero.
doi:10.1371/journal.pone.0038816.g001
Global Stop TB Plan and Global Fund Allocations
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mainly in EECA region, and by the future overall efficiency and
effectiveness of TB treatment in this region.
During the past decade of DOTS expansion, the burden of
drug-susceptible TB cases has stabilized, with a slow decline in per
capita rates, and the total number of annual new drug sensitive TB
cases globally are falling since 2006. Especially in India and China
annual numbers of drug-susceptible cases are projected to decline
between 2011 and 2015 [9], following considerable improvement
in DOTS programmes over the past decade [22] (Figure 1). In
contrast, MDR-TB treatments are projected to increase in all
regions, as the Global Plan targets a significant improvement in
the proportion of MDR-TB cases detected and treated, from just
12% in 2009 [9] to 61% by 2015 [1]. The high per-patient cost
and comparatively lower cure rates for MDR-TB (as compared
with DOTS) provides a low immediate rate of return, especially in
EECA region. However, the health and economic consequences of
poorly controlled MDR-TB are grave with global spread and
massive future treatment costs that risk undermining global TB
control, and investing in MDR-TB diagnosis and care is highly
cost-effective in the longer term [12,13,23].
Increasing investment is needed to scale up treatment of TB/
HIV co-infection, especially in Africa. HIV testing and counsel-
ling at start of TB treatment is an important entry point to find
HIV-positive people in need of ART or pre-ART care. Among
TB/HIV-coinfected patients, investment in ART has a dispro-
portionally high rate of return as it greatly reduces mortality
during DOTS [24]. When considering the cost of ART for just
the six months of DOTS, ART is not disproportionally
expensive, and even in sub-Saharan Africa corresponds to only
20% of total TB funding need – and in practice, not all HIV-
coinfected TB patients will start ART right away at DOTS
enrolment. For a given amount of funding, the global lives saved
are therefore strongly influenced by the balance in investment
allocations between TB/HIV management mainly in Africa, with
relatively high return for low cost, and MDR-TB management
mainly in EECA, with lowest immediate direct return for highest
cost. For countries where both TB/HIV coinfection and MDR-
TB are highly prevalent, such as South Africa, the presented
analysis implies that an important priority should remain to
prevent MDR from occurring and spreading in the first place, by
good-quality DOTS at high coverage, including among HIV-
coinfected patients who require concurrent ART for the DOTS
treatment to be successful.
Global Fund Investments in TB Control
If low- and middle-income countries maintain their share of
financing dedicated to TB control in line with GDP growth,
domestic funding will amount to US$6.5 billion annually by 2015,
based on GDP projections from the International Monetary Fund
(IMF) [25]. Under a more conservative scenario with domestic TB
funding increasing proportionally with GDP per capita, US$5.2
billion domestic funding would be available for TB control in
2015. More conservative yet, if keeping pace just with inflation,
domestic funding would total US$4.5 billion in 2015. In all cases,
domestic funding will substantially fall short of the Global Plan
need (US$8.5 billion in 2015 alone for control implementation,
excluding research and development) – underscoring the impor-
tance of continued co-financing by the Global Fund and other
donors.
Model projections show that the Global Fund could potentially
increase the health impact of its TB investments, if allocations
prioritized Africa and TB/HIV (Scenario B). Of all regions, Africa
has the highest immediate return on TB investment, because of its
high prevalence of TB/HIV co-infection, and relatively low per-
patient costs. An increased donor focus on sub-Saharan Africa is
also reasonable given the rapid rise in TB funding need from 2010
to 2015, of 82% (1.82-fold, Figure 1) much higher than the rate at
which most African countries will be able to expand domestic
contributions.
Alternatively, the prospect of controlling MDR-TB might
improve with preferential allocations to MDR-TB treatment
(Scenario C). This policy would, however, reduce lives saved
compared to the base-case, because the high per-patient cost for
MDR-TB treatment compared to DOTS, and the high per-
patient costs in eastern Europe and Central Asia, the region with
most MDR-TB, reduce the total number of treatments affordable
for the given amount of total funding. Affordability of TB control
globally will critically depend on the ability in EECA to improve
NTP effectiveness and efficiency (for both DOTS and MDR-TB),
by transitioning from the current hospital-centered service delivery
[9,26,27] to WHO-recommended cost-effective implementation
systems based on good-quality DOTS delivered through primary
outpatient facilities, thus improving cure rates and preventing the
emergence of MDR-TB [28].
Along with EECA countries, also India, China and other
rapidly advancing economies like Brazil and South Africa may be
expected to assume progressively greater domestic co-financing of
TB control, as their national incomes grow and TB burden
decreases [22]. The IMF forecasts that China and India will
Figure 2. Global Fund contribution to TB control, low- and middle-income countries. (A): Expected Global Fund TB expenditures; (B):
Corresponding proportional share in the total funding need for DOTS, MDR-TB and TB/HIV treatment. Note to Figure 2: Projections based on October
2010 donor pledges for 201122013.The projected decline after 2012 is larger for the Global Fund’s proportional contribution than for its absolute TB
expenditures, as global TB funding needs continue to rise through 2015.
doi:10.1371/journal.pone.0038816.g002
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increase their per capita GDP by 72% and 50%, respectively, from
2010 to 2015. Considering their projected 60% increase in TB
funding need over this period, the expected economic growth
would enable maintaining or increasing domestic contributions
relative to GDP – currently below those in other regions (Table 3).
Nevertheless, to complement local government funding TB
control may require continued donor co-funding for special
service areas, including for civil societies that are only just
organizing themselves, public-private mix activities, and to
strengthen community systems enhancing take-up of new services
by the poorest, most vulnerable people [29,30].
Limitations
Several limitations must be considered in interpreting findings.
First, estimates and projections of TB case incidence and mortality
are uncertain, given limitations in data especially for the highest-
burden countries. The WHO and Global Plan estimates neverthe-
less represent the most up-to-date, coherent set of estimates, based
on best available data from research studies and NTPs, expert
consensus and consultations with 90 countries [9,10].
Second, there is uncertainty about future Global Fund
expenditures, as well as on how this funding will increase the
Figure 3. Global Fund TB allocations (top), corresponding cases treated (middle) and lives saved (bottom), across services (left) and
regions (right), for three scenarios in 2015. Notes to Figure 3: Scenario A assumes that regional allocations remain in the distribution of 2007–
9 approved funding, with allocations among services following regional distributions of need according to the Global Plan to Stop TB. Scenario B
maximizes mortality impact per dollar spent. Scenario C allocates money to DOTS+ART for TB/HIV patients and to MDR-TB treatment only. For
comparison, left-most bars show results if grant distributions would exactly match total national funding needs as projected in the Global Plan. C&I:
China and India; EE&CA: EECA; L&MIC: other low and middle-income countries; SSA: sub-Saharan Africa.
doi:10.1371/journal.pone.0038816.g003
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level and quality of TB services. Projections assumed that Global
Fund expenditures will peak in 2012 [8], but this may shift as
donor contributions to the Global Fund vary over the period
2011215. Based on TB disbursements actually made in 2010 and
2011 and foreseen (as of April 2012), the 2010 Replenishment-
based projection was accurate for 2010 and 2011, but it may have
somewhat overestimated TB expenditures expected in 2012 and
2013 due to delays in donor payments relative to 2010 pledges.
Also, from 2012 onwards, each supported country must make
a minimum domestic government co-funding contribution relative
to the Global Fund’s budget, of a proportion increasing with
national income and with the years of each grant [31]. In this
context of transitioning to self-sustainability, the projections’
assumption that the Global Fund bears the full cost for a given
number of treatments will in the future become less and less
relevant. Especially in upper-middle income countries, Global
Fund grants will increasingly provide only a share of costs (e.g. for
drugs, laboratory or selected other program components), with the
remainder financed from domestic and other donor resources.
The Global Fund’s 2011 updated eligibility, prioritization and
counterpart financing policy further exclude from new grant
agreements upper-middle income countries that are part of the G-
20 [31] – so that notably China is expected to transition out from
Global Fund TB support from mid-2013, and Russia from end-
2013. In general, the increased counterpart financing require-
ments on especially upper-middle income countries should result
in a gradual shift of portfolio allocations toward lower-income
countries. A strategic re-allocation of Global Fund TB grants from
higher-capacity EECA to poorer and needier countries would,
however, require additional policies, since EECA already fund
97% of NTP budget themselves.
Projections furthermore assumed ART during DOTS to be
financed through the Global Fund’s TB funding envelope. In
practice this service is largely financed through HIV grants, so the
total Global Fund financial contribution to TB control is actually
greater than presented here.
The 2012 call for proposals called ‘Transitional Funding
Mechanism’ [32], to fund continuation of selected essential
prevention, treatment and/or care services in programs currently
financed by the Global Fund, illustrates how the Global Fund has
started tooperationalize its 2012–2016 Strategy, focusing on high-
impact interventions in those countries with the most acute need
for ongoing external support.
Third, lives saved projections focused on the immediate, and full
potential benefit of preventing deaths among patients treated. This
perspective is relevant to the short- and medium-term Strategy for
the Global Fund, which has an overall goal to save 10 million lives
over 2012 to 2016 [7]. We estimated lives saved against
a counterfactual of no TB treatment – an approach taken by the
Global Fund in earlier estimations of lives saved through Global
Fund-supported programs [33]. Recent WHO analyses instead
focused on lives saved through the DOTS and Stop TB Strategies
compared to TB control as it existed in 1995, i.e. under pre-
DOTS standards, and accounting for the less than 100% cure
rates typically observed in NTPs. This approach estimates around
four-fold fewer deaths averted per treatment [10,34]. Irrespective
of the counterfactual chosen, the lives saved estimations are
relevant to compare allocations among the three treatment
categories and the four world regions within the horizon of the
Global Fund 2012–2016 Strategy [7]. However, assessment of
longer-term effects will require a broader perspective of the
dynamics of both TB and HIV spread, including the impact of
DOTS in preventing MDR-TB emergence, and of MDR-TB
treatment in containing its subsequent spread [35,36,37,38]. Such
a dynamic projection could also consider the longer-term
implications for financial and health system resource needs of
starting TB patients on ART, where patients will have to be kept
on ART after completing DOTS treatment.
Fourth, lacking reliable NTP finance data from certain
countries, we assumed per-patient costs were fixed for all countries
within a region, and 2 for both DOTS and MDR-TB treatment
2 the same across regions except EECA. In-depth costing studies
undertaken in selected countries, however, suggest lower per-
patient costs in India and China compared to Africa, and within
sub-Saharan Africa higher cost in South Africa than in other high-
TB burden countries [27,29,39,40,41,42]. Within EECA, Russia
with the highest unit cost for both DOTS and MDR-TB [9] and
a large share in the region’s TB and MDR-TB burden increased
the regionally weighted average unit costs (Table 1) by two-fold for
DOTS and 13% for MDR-TB.
Fifth, we have not considered possible unintended consequences
of moving to an allocation algorithm based on priority interven-
tions (i.e. scenarios B and C). These will depend on co-investment
by other donors and national governments, who may or may not
shift contributions to non-Global Fund priority TB interventions
also considered cost-effective according to WHO benchmarks
[12,13,23]. More refined allocation algorithms that take into
account each country’s actual NTP funding including domestic
fiscal capacity to contribute to NTP needs were beyond the scope
of the current analysis, and should be pursued in future. Ongoing
improvements in national health financing reporting [20] will
allow donors to further refine their allocation policies and
maximize the return on investment. Regardless of allocation
policies, not all health budget contributions will be used for the
intended purpose. To reduce corrupt practices in its programs that
have led to misappropriation of funds, the Global Fund is
strengthening fiduciary oversight and financial control, including
an expanded role in the process for civil society and affected
communities [43].
Conclusion
Despite these limitations, the projections illustrate how for given
investments, the immediate mortality impact is determined by the
balance in allocations between TB/HIV management mainly in
Africa, with high return for low cost, and MDR-TB management
mainly in EECA, with lowest return for highest cost. The future
efficiency and effectiveness of TB treatment in high-cost region
EECA will critically determine worldwide costs. In the short term,
most lives will be saved through TB/HIV co-infection control in
Africa. Investing in MDR-TB diagnosis and care, using the highly
effective new technologies for diagnosis of TB and rifampicin-
resistant TB, is needed to prevent MDR-TB, reduce substantial
future costs of managing MDR-TB, and to reduce risk of
unaffordability of TB control in longer-term. For the Global
Fund, improved allocative efficiency of investments through
proactive approaches that ‘inform demand’ would result in greater
numbers of lives saved than might be with the prevailing funding
model of responding to country demand. While an investment
approach that fosters value for money improves allocative
efficiency and aggregate health impact, two key considerations of
the Global Fund’s 201222016 Strategy [7], it does not address
equity and political dimensions of resource allocation, which must
be considered. Alongside country financing gaps, absorptive and
co-financing capacities and equity considerations, these allocation
scenarios will help the Global Fund, other international donors
and NTPs to implement more effective, evidence-based in-
vestment approaches focusing on highest-impact populations and
interventions.
Global Stop TB Plan and Global Fund Allocations
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